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The study by Minuk and colleagues entitled ‘‘Daily Cip-
roﬂoxacin Treatment for Patients with Advanced Liver
Disease Awaiting Liver Transplantation Reduces Hospi-
talizations’’ [1] tested the hypothesis that patients on the
liver transplant list may beneﬁt from antibiotics as a
method of enhancing hepatic regeneration and improving
liver function. The authors had previously shown in a rat
model of acute and subacute liver failure that antibiotics
improved survival [2, 3] and that antibiotics appeared to
also improve survival in a model of chronic liver injury [4].
This beneﬁt correlated in these animal models with
improvement in markers of hepatic regeneration. In the
current study, the authors asked whether the same beneﬁt
might be found in cirrhotic patients on the liver transplant
waiting list.
This single-site, prospective, randomized, double-blind
study measured routine markers of hepatic function
(albumin, bilirubin, and international normalized ratio for
prothrombin time [INR]), markers of hepatic inﬂammation
(aspartate aminotransferase [AST] and alanine amino-
transferase [ALT]), and clinical outcomes (hospitalizations,
hepatic encephalopathy, etc.) after 1 or 3 months of treat-
ment with placebo or ciproﬂoxacin 250–500 mg twice
daily. Results showed no systematic beneﬁt at 1 or
3 months in markers of hepatic function or inﬂammation,
and a signiﬁcant improvement in albumin at 1 month was
not conﬁrmed at 3 months. However, it should be noted
that more precise measurements of hepatic function [5, 6]
or markers of regeneration might have shown subclinical
beneﬁts that would have been encouraging for further
studies. Potential beneﬁts in hospitalizations and clinical
outcomes were also assessed. There were fewer hospital-
izations for hepatic encephalopathy among subjects
receiving ciproﬂoxacin, but little beneﬁt for other clinical
outcomes. As the authors note, antibiotics are helpful in
treating encephalopathy and in prophylaxis against spon-
taneous bacterial peritonitis [7–10]. The effect of antibi-
otics on improvement in survival among variceal bleeders
has been profound [11]. Thus, the reduction in hospital-
izations among patients receiving antibiotics in this study is
not surprising, and hepatic regeneration is not required to
explain this improvement. Thus, the beneﬁts of antibiotics
in animal models of acute and chronic liver injury were not
conﬁrmed in this clinical trial among patients with
advanced cirrhosis on the liver transplant waiting list.
Animal models have been very useful in the evaluation
of the pathophysiology of portal hypertension, ascites and
hepatic ﬁbrosis [12–17]. Why was so little beneﬁt observed
when antibiotics were used in humans with cirrhosis as
compared with animal models? The answer partially lies in
the difference between changes in pathophysiology in
animal models of acute liver injury and humans with cir-
rhosis, who have dense hepatic ﬁbrosis that develops over
long periods of time and resolves slowly when the insult is
stopped [18, 19]. By contrast, animal models of cirrhosis
generally require continued liver injury to produce cirrho-
sis, and ﬁbrosis resolves rapidly if the insult is stopped
[12–17]. Furthermore, there is often a complex interaction
of factors contributing to hepatic injury that includes bac-
terial products such as endotoxin from the gut that may be
less important in man [12–14]. Antibiotics markedly
decrease injury in most animal models [12–14]. Therefore,
study of the pathophysiology of liver injury and compli-
cations of liver disease in animal models has been very
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DOI 10.1007/s10620-011-1578-1valuable, but the regression of liver ﬁbrosis differs between
humans and animals. Thus, ﬁndings in animal models must
be conﬁrmed in clinical settings, and we applaud the
authors for testing their hypothesis in humans [1]. Unfor-
tunately, this study shows that antibiotics do not enhance
hepatic regeneration or improve clinical outcomes by
means of regeneration in patients on the liver transplant
list.
According to several recent studies, there is no experi-
mental model that completely reproduces human liver
ﬁbrosis [12–14]. Since there are contraindications to serial
liver biopsies in humans with liver disease, studies of
genetic and molecular aspects of liver injury and ﬁbrosis
should continue. An initial approach should involve
exploration of the molecular mechanisms of liver ﬁbrosis
in different diseases [20]. This might elucidate areas of
potential efﬁcacy of ciproﬂoxacin and other ﬂuoroquino-
lones. Ultimately, all beneﬁts in animals must be conﬁrmed
by clinical trials in man.
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